Invivo Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Invivo's estimated annual revenue is currently $53M per year.(i)
  • Invivo's estimated revenue per employee is $251,000

Employee Data

  • Invivo has 211 Employees.(i)
  • Invivo grew their employee count by -23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.1M1040%$63.5MN/A
#2
$14.3M57-8%N/AN/A
#3
$33.1M1326%N/AN/A
#4
$10.8M435%N/AN/A
#5
$488.3M12160%N/AN/A
#6
$14.3M5710%N/AN/A
#7
$5M20-9%N/AN/A
#8
$95.6M381-1%N/AN/A
#9
$16.8M673%N/AN/A
#10
$57M22713%N/AN/A
Add Company

What Is Invivo?

Invivo Corporation designs, manufactures and markets monitoring systems that measure and display vital signs of patients in medical settings for use in both magnetic resonance imaging (MRI) environments and in general patient monitoring applications. The Company's systems simultaneously monitor heart function, respiration, heart rate, blood oxygen levels, invasive and non-invasive blood pressure and exhaled carbon dioxide levels. Invivo is also engaged in the industrial instrumentation business. It designs, manufactures and markets sensor-based instruments primarily for industrial process control applications. The Company sells its patient monitoring products primarily to hospitals and to stand-alone imaging centers, outpatient surgery centers and original equipment manufacturer (OEM) customers. Invivo markets its industrial instrumentation products primarily to various industrial users. In January 2004, the Company was acquired via merger by Intermagnetics General Corporation. (Source: 10-K)

keywords:N/A

N/A

Total Funding

211

Number of Employees

$53M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Invivo News

2022-04-20 - Study reports an orally available SARS-CoV-2 Mpro inhibitor ...

In the present study, researchers assessed the efficiency of a SARS-CoV-2 Mpro inhibitor in exhibiting potent antiviral activity in vivo against...

2022-04-20 - Kelonia Scores $50M to Propel In Vivo Gene Delivery Platform

Kelonia accomplishes this by combining chimeric antigen receptor (CAR) T cell immunology with precision in-vivo targeting.

2022-04-17 - InVivo Therapeutics (NASDAQ:NVIV) Receives New ...

The firm set a “sell” rating on the biotechnology company's stock. Shares of NVIV opened at $0.23 on Wednesday. InVivo Therapeutics has a fifty-...

2022-04-17 - InVivo Therapeutics (NASDAQ:NVIV) Receives New ...

The firm set a “sell” rating on the biotechnology company's stock. Shares of NVIV opened at $0.23 on Wednesday. InVivo Therapeutics has a fifty-...

2022-03-30 - Invivo X Unity: First Official Prosecco of Eurovision to launch

Innovative and multi award-winning Invivo is launching a new Eurovision Song Contest wine range: Invivo X Unity. Featuring a Prosecco DOC...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$63.9M2151%N/A
#2
$48.7M21614%N/A
#3
$60.4M2169%N/A
#4
$43M217N/AN/A
#5
$67.1M2262%N/A